

CURRICULUM VITAE

Tuomo Valdemar Alanko

Date of birth: Dec 1st 1966

Citizenship: Finland

Education

MD, University of Helsinki, Faculty of Medicine 1992

Licensed physician 1993

Ph.D. (Thesis), University of Helsinki, Faculty of Medicine 2001

Specialist in clinical oncology 2005

Professional experience, Biomedical research

Department of Virology, Haartman Institute, University of Helsinki

Research assistant Dec 1st-Dec 31st 1988, June 1st-July 11th 1989

Scientist Sept 1st-Sept 30th 1994

Assistant teacher (Scientist) approx 3 years in several periods 1992-1998

Department of Dermatology, Helsinki University Central Hospital

Scientist June 1st-Sept 30th 1995, Feb 1st-April 30th 1997, Oct 1st-Dec 31st 1997,

Jan 1st-May 31st 1999

Professional experience, Clinical research

Clinical investigator in several phase I-III studies 2002-

Regular GCP training; most recent training Feb 2nd, 2015 (TransCelerate)

Professional experience, Clinical oncology

Department of Oncology, Helsinki University Central Hospital

Resident (Oncology) Jan 2nd-May 31st 2001, Sep 3rd 2001-May 31st 2005

Specialist in Oncology (section for hepatopancreaticobiliary and gastrointestinal tumors)

Jun 1st 2005-Aug 31st 2009 (off duty Sep 1st 2008-Aug 31st 2009)

Professional experience, Pharma industry

AstraZeneca Marketing company Finland

Medical Affairs Manager (oncology) Sep 1st 2008-July 29th 2009

Current position

Docrates Cancer Center, Saukonpaadenranta 2, 00180 Helsinki, Finland

Chief Physician (Medical oncology) Aug 1st 2009-

Other roles

Valvira (National Supervisory Authority for Welfare and Health)

Permanent medical consultant Dec 1st 2012-

Colores (Finnish Colorectal Cancer Patient Association)

Chairman of the executive board 2016-

Original publications in international peer-reviewed journals:

- Tienari, J., T. Alanko, E. Lehtonen, O. Saksela: The expression and localization of urokinase-type plasminogen activator and its type 1 inhibitor are regulated by retinoic acid and fibroblast growth factor in human teratocarcinoma cells. *Cell Regulation* 2: 285-297, 1991
- Alanko, T., J. Tienari, E. Lehtonen, O. Saksela: Development of FGF-dependency in human embryonic carcinoma cells after retinoic acid-induced differentiation. *Developmental Biology* 161:141-153, 1994
- Tienari, J., T. Alanko, O. Saksela, M. Vesterinen, E. Lehtonen: Fibroblast growth factor-mediated stimulation of differentiating teratocarcinoma cells: Evidence for paracrine growth regulation. *Differentiation* 59: 193-199, 1995
- Alanko, T., J. Tienari, E. Lehtonen, O. Saksela: FGF-2 inhibits apoptosis in human teratocarcinoma cells during differentiation on collagen substratum. *Experimental Cell Research* 228: 306-312, 1996
- Bhowmik, A., H. Paimela, T. Joutsu, T. Alanko, T. Paavonen, O. Saksela, E. Kivilaakso: Induction of proliferation in isolated guinea pig gastric epithelium during restitution after superficial injury. *Digestive Diseases and Sciences* 43: 1507-1512, 1998
- Alanko, T., M. Rosenberg, O. Saksela: FGF expression allows nevus cells to survive in three-dimensional collagen gel under conditions that induce apoptosis in normal human melanocytes. *Journal of Investigative Dermatology* 113: 111-116, 1999
- Alanko, T., O. Saksela: Transforming growth factor β 1 induces apoptosis in normal melanocytes but not in nevus cells in type I collagen. *Journal of Investigative Dermatology* 115: 286-291, 2000
- von Willebrand, M., K. Kohler, T. Alanko, M. Laiho, O. Saksela: FGF-2 blocks TGF-beta1-mediated suppression of Bcl-2 in normal melanocytes. *Experimental Dermatology* 14: 202-208, 2005
- Joensuu H., P.L. Kellokumpu-Lehtinen, P. Bono, T. Alanko, V. Kataja, R. Asola, T. Utriainen, R. Kokko, A. Hemminki, M. Tarkkanen, T. Turpeenniemi-Hujanen, S. Jyrkkio, M. Flander, L. Helle, S. Ingalsuo, K. Johansson, AS. Jaaskelainen, M. Pajunen, M. Rauhala, J. Kaleva-Kerola, T. Salminen, M. Leinonen, I. Elomaa, J. Isola, FinHer Study Investigators: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. *New England Journal of Medicine* 354: 809-820, 2006
- Bono P., H. Elfving, T. Utriainen, P. Osterlund, T. Saarto, T. Alanko, H. Joensuu: Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. *Annals of Oncology* 20:393-4, 2009
- Bono P., P.L. Kellokumpu-Lehtinen, T. Alanko, R. Kokko, R. Asola, T. Turpeenniemi-Hujanen, S. Jyrkkio, V. Kataja, M. Leinonen, H. Joensuu: Docetaxel 100 versus 80 mg/m² as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial. *Annals of Oncology* 20:595-6, 2009
- Joensuu H., P. Bono, V. Kataja, T. Alanko, R. Kokko, R. Asola, T. Utriainen, T. Turpeenniemi-Hujanen, S. Jyrkkio, K. MÖykkynen, L. Helle, S. Ingalsuo, M. Pajunen, M. Huusko, T. Salminen, P. Auvinen, H. Leinonen, M. Leinonen, J. Isola, P.L. Kellokumpu-Lehtinen: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. *Journal of Clinical Oncology* 27:5685-92, 2009
- Joensuu H., L. Sailas, T. Alanko, K. Sunela, R. Huuhtanen, M. Utriainen, R. Kokko, P. Bono, T. Wigren, S. Pyrhönen, T. Turpeenniemi-Hujanen, R. Asola, M. Leinonen, M. Hahka-Kemppinen, P. Kellokumpu-Lehtinen: Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. *Annals of Oncology* 21:968-73, 2010
- Österlund P., L.M. Soveri, H. Isoniemi, T. Poussa, T. Alanko, P. Bono: Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. *British Journal of Cancer* 104:599-604, 2011
- Pesonen S., I. Diaconu, L. Kangasniemi, T. Ranki, A. Kanerva, S.K. Pesonen, U. Gerdemann, A.M. Leen, K. Kairemo, M. Oksanen, E. Haavisto, S.L. Holm, A. Karioja-Kallio, S. Kauppinen, K.P. Partanen, L. Laasonen, T. Joensuu, T. Alanko, V. Cerullo, A. Hemminki: Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. *Cancer Research* 72:1621-31, 2012
- Kanerva A, P. Nokisalmi, I. Diaconu, A. Koski, V. Cerullo, I. Liikanen, S. Tähtinen, M. Oksanen, R. Heiskanen, S. Pesonen, T. Joensuu, T. Alanko, K. Partanen, L. Laasonen, K. Kairemo, S. Pesonen, L. Kangasniemi, A. Hemminki: Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. *Clinical Cancer Research* 19:2734-44, 2013

- Osterlund P., R. Peltonen, T. Alanko, P. Bono, H. Isoniemi: A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. *Onco. Targets Ther.* 7:1177-84, 2014
- Kiljunen T., A. Kangasmäki, A. Aaltonen, K. Kairemo, K. Partanen, G. Joensuu, T. Alanko, L. Vaalavirta, T. Joensuu: VMAT technique enables concomitant radiotherapy of prostate cancer and pelvic bone metastases. *Acta Oncologica* Oct 13:1-7, 2014 [Epub ahead of print]
- Ranki T., T. Joensuu, E. Jäger, J. Karbach, C. Wahle, K. Kairemo, T. Alanko, K. Partanen, R. Turkki, N. Linder, J. Lundin, A. Ristimäki, M. Kankainen, A. Hemminki, C. Backman, K. Diemel, M. von Euler, E. Haavisto, T. Hakonen, J. Juhila, M. Jäderberg, P. Priha, L. Vassilev, A. Vuolanto, S. Pesonen: Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization. *OncoImmunology* 3, 2014, e958937, doi:10.4161/21624011.2014.958937
- Vassilev L., T. Ranki, T. Joensuu, E. Jäger, J. Karbach, C. Wahle, K. Partanen, K. Kairemo, T. Alanko, R. Turkki, N. Linder, J. Lundin, A. Ristimäki, M. Kankainen, A. Hemminki, C. Backman, K. Diemel, M. von Euler, E. Haavisto, T. Hakonen, J. Juhila, M. Jäderberg, P. Priha, Vuolanto, S. Pesonen: Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8(+) T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. *Oncoimmunology* 4, 2015, e1017702
- Ranki T., S. Pesonen, A. Hemminki, K. Partanen, K. Kairemo, T. Alanko, J. Lundin, N. Linder, R. Turkki, A. Ristimäki, E. Jäger, J. Karbach, C. Wahle, M. Kankainen, C. Backman, M. von Euler, E. Haavisto, T. Hakonen, R. Heiskanen, M. Jäderberg, J. Juhila, P. Priha, L. Suoranta, L. Vassilev, A. Vuolanto, T. Joensuu: Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. *J Immunother Cancer* Mar 15;4:17, 2016. doi: 10.1186/s40425-016-0121-5. eCollection 2016.
- Joensuu T., G. Joensuu, K. Kairemo, T. Kiljunen, M. Riener, A. Aaltonen, M. Ala-Opas, A. Kangasmäki, T. Alanko, L. Taipale, P. Hervonen, A. Butzow, I. Virgolini, A. Hemminki: Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation. *Anticancer Res* 36: 6439-48, 2016. doi:10.21873/anticancer.11242

Publications in Finnish medical journals:

- Janes R., P. Vieira, M. Saarela, K. Aaltonen, T. Alanko, S. Siitonen, M.L. Karjalainen-Lindsberg: [Diagnostinen ongelmatapaus: ihomuutokset ja etenevät keskushermosto-oireet lymfooman ilmentymänä]. *Duodecim* 123:413-8, 2007 (Case report in Finnish)
- Ristimäki R., H. Isoniemi, T. Alanko: [Hepatosellulaarisen karsinoman hoito] Hepatocellular carcinoma. *Suomen Lääkärilehti (Finnish Medical Journal)* 64:1669–1674, 2009 (Review in Finnish, English summary available at www.laakarilehti.fi > In English)

Helsinki Mar 2nd, 2017

Tuomo Alanko